Antimicrobial Agents Practice Questions

Q: Which of the following antibiotics is not used in the treatment of enterococcal infections?

Cephalexin. **Explanation:** The correct answer is **Cephalexin (Option D)**. The fundamental pharmacological concept to remember for NEET-PG is that **Enterococci are inherently resistant to all Cephalosporins.** This is due to the low affinity of enterococcal Penicillin-Binding Proteins (PBPs), specifically PBP5, for cephalosporins. Therefore, regardless of the generation, cephalosporins (like Cephalexin, a 1st generation agent) are never used to treat enterococcal infections. **Analysis of Options:** * **Vancomycin (Option A):** A glycopeptide that is traditionally the drug of choice for serious ampicillin-resistant enterococcal infections. It inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus. * **Linezolid (Option B):** An oxazolidinone used primarily for Vancomycin-Resistant Enterococci (VRE). It inhibits protein synthesis by binding to the 50S ribosomal subunit. * **Teicoplanin (Option C):** Another glycopeptide similar to Vancomycin. It is effective against many strains of *Enterococcus faecalis* and *E. faecium*, though some VRE strains (VanA phenotype) are also resistant to it. **High-Yield Clinical Pearls for NEET-PG:** 1. **LAME mnemonic:** Cephalosporins lack activity against **L**isteria, **A**typicals (Mycoplasma/Chlamydia), **M**RSA (except Ceftaroline), and **E**nterococci. 2. **Synergy:** For serious enterococcal infections (e.g., endocarditis), an aminoglycoside (Gentamicin) is added to a cell-wall active agent (Ampicillin or Vancomycin) for bactericidal synergy. 3. **Drug of Choice:** For uncomplicated *E. faecalis*, **Ampicillin** remains the first-line treatment. For VRE, **Linezolid** or **Daptomycin** are preferred.

Q: A 29-year-old female diagnosed with AIDS presents with progressive blurring of vision in her right eye. Fundoscopic examination reveals a small, white, opaque lesion on the retina. What is the most appropriate therapy for this patient?

Ganciclovir. The clinical presentation of progressive blurring of vision and a white, opaque retinal lesion in a patient with AIDS is highly suggestive of **CMV Retinitis**. This is the most common opportunistic ocular infection in HIV-infected individuals, typically occurring when the CD4 count falls below 50 cells/mm³ [1, 2]. **1. Why Ganciclovir is Correct:** Ganciclovir is the first-line treatment for CMV infections [1, 2]. It is a guanosine analogue that requires initial phosphorylation by a viral protein kinase (**UL97**) to ganciclovir monophosphate, followed by conversion to the triphosphate form by host cell kinases. This active form competitively inhibits viral DNA polymerase, terminating CMV DNA synthesis. **2. Why Other Options are Incorrect:** * **Acyclovir:** Primarily used for HSV and VZV. It is ineffective against CMV because CMV lacks the viral thymidine kinase required to activate acyclovir. * **Amantadine:** An antiviral agent used for Influenza A (by inhibiting the M2 ion channel) and Parkinson’s disease. It has no activity against DNA viruses like CMV. * **Flucytosine:** An antifungal agent used in combination with Amphotericin B for Cryptococcal meningitis. It has no antiviral properties. **High-Yield Clinical Pearls for NEET-PG:** * **CMV Retinitis Appearance:** Often described as "pizza-pie" or "cottage cheese and ketchup" appearance (hemorrhage with exudates). * **Side Effects:** The dose-limiting toxicity of Ganciclovir is **bone marrow suppression** (neutropenia, thrombocytopenia). * **Alternative Drugs:** If Ganciclovir resistance occurs (UL97 mutation), **Foscarnet** or **Cidofovir** are used; these do not require viral phosphorylation for activation [3]. * **Valganciclovir:** The oral prodrug of ganciclovir, often used for maintenance therapy [3].

Q: Which of the following is NOT a NNRTI?

Ritonavir. The correct answer is **Ritonavir** because it belongs to the **Protease Inhibitor (PI)** class of antiretroviral therapy (ART), not the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) class. ### **Explanation of Options** * **Ritonavir (Option A):** This is a Protease Inhibitor. In modern clinical practice, it is primarily used as a **"pharmacokinetic enhancer" (booster)**. It inhibits the CYP3A4 enzyme, thereby increasing the plasma concentrations and half-life of other protease inhibitors (like Lopinavir or Atazanavir). * **Nevirapine (Option B):** A first-generation NNRTI. It is well-known for its role in preventing mother-to-child transmission of HIV, though it is associated with a high risk of hepatotoxicity and severe skin rashes (Stevens-Johnson Syndrome). * **Efavirenz (Option C):** A first-generation NNRTI. It is a high-yield topic due to its unique side effect profile, including **neuropsychiatric symptoms** (vivid dreams, insomnia, psychosis) and potential teratogenicity (neural tube defects). * **Delavirdine (Option D):** A first-generation NNRTI. It is less commonly used in clinical practice today but remains a classic textbook example of the NNRTI class. ### **High-Yield Clinical Pearls for NEET-PG** 1. **Mechanism of Action:** NNRTIs bind to a **hydrophobic pocket** (allosteric site) on the HIV-1 Reverse Transcriptase enzyme, causing a conformational change. Unlike NRTIs, they do *not* require phosphorylation to become active and do *not* compete with nucleosides. 2. **Class Specificity:** NNRTIs are active only against **HIV-1**, whereas NRTIs and PIs are active against both HIV-1 and HIV-2. 3. **Second Generation NNRTIs:** Remember **Etravirine** and **Rilpivirine**; these are often used when resistance develops to first-generation agents. 4. **Mnemonic for NNRTIs:** "The **NED** family" (**N**evirapine, **E**favirenz, **D**elavirdine).

Q: Clavulanic acid is given in combination with amoxicillin in order to:

Extend amoxicillin's antibacterial spectrum. **Explanation:** The correct answer is **D. Extend amoxicillin's antibacterial spectrum.** **Mechanism of Action:** Amoxicillin is a beta-lactam antibiotic that is susceptible to degradation by **beta-lactamase enzymes** produced by certain bacteria (e.g., *Staphylococcus aureus*, *H. influenzae*, and *E. coli*). Clavulanic acid is a **"suicide inhibitor"** of beta-lactamase. It has negligible antibacterial activity of its own but binds irreversibly to the beta-lactamase enzyme, protecting amoxicillin from destruction. This allows amoxicillin to inhibit bacterial cell wall synthesis in organisms that would otherwise be resistant, thereby effectively **extending its spectrum** to include beta-lactamase-producing strains. **Analysis of Incorrect Options:** * **A. Reduce allergic reactions:** Clavulanic acid does not modulate the immune system; hypersensitivity reactions (Type I-IV) are inherent to the penicillin structure itself. * **B. Prolong half-life:** The half-life of amoxicillin is determined by renal excretion. Clavulanic acid does not interfere with the renal tubular secretion of amoxicillin (unlike Probenecid, which does). * **C. Reduce diarrhea:** In fact, the combination (Co-amoxiclav) is **more likely** to cause diarrhea and GI upset than amoxicillin alone, as clavulanic acid increases gut motility. **High-Yield NEET-PG Pearls:** * **Other Beta-lactamase Inhibitors:** Sulbactam (paired with Ampicillin) and Tazobactam (paired with Piperacillin). * **Suicide Inhibition:** Clavulanic acid is the classic example where the inhibitor is chemically modified by the enzyme during the process of inhibition. * **Clinical Note:** Co-amoxiclav is a notorious cause of **drug-induced cholestatic jaundice**, a side effect specifically attributed to the clavulanate component.

Q: In cotrimoxazole, what is the ratio of sulphamethoxazole to trimethoprim?

5:1. The original explanation provided the answer details without citations. **Cotrimoxazole** is a fixed-dose combination of **Sulphamethoxazole (SMZ)** and **Trimethoprim (TMP)**. [1] The correct ratio in the formulation is **5:1** (e.g., 400 mg SMZ + 80 mg TMP). [3] **1. Why 5:1 is the Correct Answer:** While both drugs act on the same metabolic pathway (folic acid synthesis), they have different pharmacokinetic profiles. [1] Trimethoprim is significantly more lipid-soluble and has a larger volume of distribution than Sulphamethoxazole. To achieve the **optimal synergistic plasma concentration ratio of 20:1** (which is required for maximum bactericidal effect), the drugs must be administered in a **5:1 dose ratio**. [3] This compensates for the difference in their distribution and clearance rates. [4] **2. Analysis of Incorrect Options:** * **A (2:1) & B (1:1):** These ratios would result in insufficient plasma levels of Trimethoprim relative to Sulphamethoxazole, failing to reach the 20:1 steady-state plasma concentration needed for synergy. * **D (4:5):** This is mathematically incorrect and does not align with any standard pharmacological preparation of these agents. [3] **3. NEET-PG High-Yield Clinical Pearls:** * **Mechanism of Action:** Sequential blockade of folate synthesis. [2] SMZ inhibits *Dihydropteroate synthase*, while TMP inhibits *Dihydrofolate reductase*. [1] * **Nature of Action:** Individually, both drugs are bacteriostatic; in combination (Cotrimoxazole), they become **bactericidal**. [2][3] * **Drug of Choice (DOC):** Cotrimoxazole remains the DOC for *Pneumocystis jirovecii* pneumonia and *Stenotrophomonas maltophilia*. [3] * **Adverse Effects:** Watch for Megaloblastic anemia (due to folate deficiency) and Stevens-Johnson Syndrome (due to the sulfonamide component). [3]

Q: Which drug is known to produce Stevens-Johnson syndrome in HIV-infected individuals?

Thioacetazone. **Explanation:** **Thioacetazone** is a bacteriostatic second-line anti-tubercular drug. The correct answer is C because Thioacetazone is notorious for causing severe, life-threatening cutaneous adverse drug reactions (CADR), specifically **Stevens-Johnson Syndrome (SJS)** and **Toxic Epidermal Necrolysis (TEN)**, in patients with HIV co-infection. The risk is significantly higher in this population due to altered immune responses and glutathione deficiency. Consequently, the WHO and national guidelines (including NTEP) strictly contraindicate the use of Thioacetazone in HIV-positive individuals. **Analysis of Incorrect Options:** * **A. Paraaminosalicylate (PAS):** Primarily causes gastrointestinal distress (nausea, vomiting, diarrhea) and hypersensitivity reactions like skin rashes or drug-induced hepatitis, but it is not specifically linked to SJS in HIV patients. * **B. Cycloserine:** Known for its **neuropsychiatric side effects** (the "psych-drug"), including seizures, psychosis, and depression. It does not typically cause severe cutaneous reactions. * **D. Rifampicin:** Commonly causes a harmless orange discoloration of body fluids (urine, sweat, tears) and hepatotoxicity. While it can cause "flu-like syndrome," it is not the primary culprit for SJS in the context of HIV. **High-Yield Clinical Pearls for NEET-PG:** * **Thioacetazone Rule:** Never prescribe Thioacetazone to a patient unless their HIV status is confirmed negative. * **Other SJS Culprits in HIV:** Apart from Thioacetazone, **Nevirapine** (an NNRTI) and **Sulfonamides** (like Cotrimoxazole) are the most common causes of SJS in HIV-infected individuals. * **Mechanism:** Thioacetazone inhibits mycolic acid synthesis (similar to Isoniazid) but is rarely used today due to its toxicity profile.

Q: Which drug is known to cause red cell aplasia?

Chloramphenicol. **Explanation:** **Chloramphenicol** is a broad-spectrum antibiotic that inhibits the 50S ribosomal subunit. Its most significant and dreaded adverse effect is **bone marrow suppression**, which occurs in two distinct forms: 1. **Dose-dependent suppression:** A reversible reduction in erythropoiesis (leading to anemia, leukopenia, or thrombocytopenia) due to the inhibition of mitochondrial protein synthesis. 2. **Dose-independent (Idiosyncratic) Aplastic Anemia:** A rare but often fatal condition where the bone marrow fails to produce all three blood cell lines (pancytopenia). This includes **pure red cell aplasia**, where there is a selective failure of red blood cell production. **Analysis of Incorrect Options:** * **A. Aminoglycosides:** Primarily known for **ototoxicity** (vestibular and cochlear damage) and **nephrotoxicity** (acute tubular necrosis). They do not typically affect the bone marrow. * **C. Penicillin:** Most commonly associated with **hypersensitivity reactions** (Type I IgE-mediated anaphylaxis). While high doses can rarely cause hemolytic anemia (Type II hypersensitivity), they do not cause red cell aplasia. * **D. Ciprofloxacin:** A fluoroquinolone known for causing **tendon rupture** (Achilles tendon), cartilage damage in children, and QT interval prolongation. It is not associated with bone marrow failure. **High-Yield Clinical Pearls for NEET-PG:** * **Gray Baby Syndrome:** Occurs in neonates due to deficient **glucuronyl transferase** enzyme, leading to chloramphenicol accumulation, cyanosis, and circulatory collapse. * **Mechanism of Resistance:** Primarily via the production of **chloramphenicol acetyltransferase**. * **Drug of Choice:** Though limited by toxicity, it remains a backup for enteric fever (Typhoid) and bacterial meningitis in patients with severe penicillin allergies.

Q: Which antimalarial agent is safe for use in pregnancy?

Proguanil. ### Explanation **Correct Option: D (Proguanil)** Proguanil is considered safe for use during pregnancy, especially when combined with Chloroquine for malaria prophylaxis. It acts as a dihydrofolate reductase inhibitor. While it interferes with folate metabolism, clinical data has not shown an increased risk of congenital malformations or adverse pregnancy outcomes, provided it is administered with **folic acid supplementation** (5 mg daily) to counteract potential folate deficiency. **Analysis of Incorrect Options:** * **A. Atovaquone:** Generally avoided in pregnancy due to a lack of adequate human safety data. When combined with proguanil (Malarone), it is only recommended if the potential benefit justifies the unknown risk to the fetus. * **B. Pyrimethamine:** While used in some combinations (like Sulfadoxine-Pyrimethamine for IPTp), it is a potent folate antagonist. High doses are potentially teratogenic, particularly in the first trimester, making it less "safe" as a standalone choice compared to Proguanil. * **C. Primaquine:** **Strictly contraindicated** in pregnancy. It can cross the placenta and cause severe **hemolysis** in the fetus if the fetus is G6PD deficient. It is reserved for radical cure post-delivery. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Chloroquine remains the DOC for sensitive *P. falciparum* and *P. vivax* in all trimesters of pregnancy. * **Resistant Malaria:** For Chloroquine-resistant strains, **Quinine + Clindamycin** is the preferred regimen in the first trimester. **ACT (Artemisinin-based Combination Therapy)** is now recommended by the WHO for the second and third trimesters. * **Contraindicated Antimalarials:** Primaquine, Tetracycline, Doxycycline, and Halofantrine.

Q: What is the drug of choice for treating Strongyloides stercoralis infection?

Ivermectin. **Explanation:** **Ivermectin** is the drug of choice for **Strongyloidiasis** (*Strongyloides stercoralis*). Unlike many other intestinal helminths, *Strongyloides* has a unique life cycle involving autoinfection, which can lead to life-threatening hyperinfection syndrome in immunocompromised patients. Ivermectin works by intensifying GABA-mediated neurotransmission and binding to glutamate-gated chloride channels, causing flaccid paralysis and death of the parasite. It is preferred over azoles due to its higher efficacy and shorter treatment duration (usually a single dose or two doses). **Analysis of Incorrect Options:** * **Albendazole:** While it has activity against *Strongyloides*, it is considered a second-line agent. It requires a longer course (3–7 days) and has lower cure rates compared to Ivermectin. It remains the drug of choice for Hydatid disease and Neurocysticercosis. * **Mebendazole:** It has poor systemic absorption and is generally ineffective against the tissue-migrating stages of *Strongyloides*. It is primarily used for pinworm, whipworm, and hookworm infections. * **Levamisole:** This agent acts as a nicotinic acetylcholine receptor agonist. While used for Ascariasis in the past, it is rarely used now due to toxicity (agranulocytosis) and is not effective for Strongyloidiasis. **High-Yield Clinical Pearls for NEET-PG:** * **DOC for Strongyloidiasis & Onchocerciasis (River Blindness):** Ivermectin. * **Mazzotti Reaction:** A severe immune response (fever, rash, hypotension) seen after treating Onchocerciasis with Ivermectin; managed with steroids. * **Hyperinfection Syndrome:** Always suspect in patients on steroids or with HTLV-1 infection presenting with *Strongyloides*. * **Ivermectin Safety:** Avoid in patients with a breached blood-brain barrier (e.g., meningitis) as it may cross and cause CNS depression.

Question 1

Which of the following antibiotics is not used in the treatment of enterococcal infections?

Accepted Answer

Cephalexin

Answer

Vancomycin

Answer

Linezolid

Answer

Teichoplanin

Question 2

A 29-year-old female diagnosed with AIDS presents with progressive blurring of vision in her right eye. Fundoscopic examination reveals a small, white, opaque lesion on the retina. What is the most appropriate therapy for this patient?

Accepted Answer

Ganciclovir

Answer

Acyclovir

Answer

Amantadine

Answer

Flucytosine

Question 3

Which of the following is NOT a NNRTI?

Accepted Answer

Ritonavir

Answer

Nevirapine

Answer

Efavirenz

Answer

Delavirdine

Question 4

Clavulanic acid is given in combination with amoxicillin in order to:

Accepted Answer

Extend amoxicillin's antibacterial spectrum

Answer

Reduce the risk of allergic reactions

Answer

Prolong amoxicillin's half-life

Answer

Reduce the severity of diarrhea

Question 5

In cotrimoxazole, what is the ratio of sulphamethoxazole to trimethoprim?

Accepted Answer

5:1

Answer

2:1

Answer

1:1

Answer

4:5

Question 6

Which drug is known to produce Stevens-Johnson syndrome in HIV-infected individuals?

Accepted Answer

Thioacetazone

Answer

Paraaminosalicylate

Answer

Cycloserine

Answer

Rifampicin

Question 7

Which drug is known to cause red cell aplasia?

Accepted Answer

Chloramphenicol

Answer

Aminoglycosides

Answer

Penicillin

Answer

Ciprofloxacin

Question 8

What is the mechanism of action of Acyclovir?

Accepted Answer

Inhibition of viral DNA polymerase, requiring initial phosphorylation by viral thymidine kinase

Answer

Inhibition of viral DNA polymerase

Answer

Inhibition of viral thymidine kinase

Answer

Inhibition of viral reverse transcriptase

Question 9

Which antimalarial agent is safe for use in pregnancy?

Accepted Answer

Proguanil

Answer

Atovaquone

Answer

Pyrimethamine

Answer

Primaquine

Question 10

What is the drug of choice for treating Strongyloides stercoralis infection?

Accepted Answer

Ivermectin

Answer

Mebendazole

Answer

Albendazole

Answer

Levamisole

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?